By Bhanvi Satija LONDON, April 1 (Reuters) - Vaccine makers Pfizer and BioNTech halted a large U.S. trial of their updated ...

BioNTech will wind up its vaccine manufacturing plant in Singapore by February 2027 after a strategic review. Read more at ...

The trial is tied to a post-marketing commitment that FDA Commissioner Martin Makary put in place last year for all approved ...

On the heels of a comprehensive review, BioNTech has decided “to close its planned Singapore site by the end of February 2027 ...

Pfizer BioNTech halt COVID vaccine study in adults 50-64 due to slow enrollment, citing inability to generate relevant postmarketing data.

The German biotechnology company currently employs 85 people at its manufacturing plant in Tuas.

COVID-19 partners Pfizer and BioNTech have been unable to recruit healthy adults aged 50 to 64 fast enough to deliver ...

Vaccine maker's critics hope for new attorney general to reverse Pam Bondi's hostility to clinical trial whistleblower's ...

Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences ...

Presentations showcase progress in BioNTech’s late-stage lung cancer programs, reinforcing the potential of the Company’s differentiated ...

The founders of the biotech company that developed Comirnaty, the mRNA-based COVID-19 vaccine sold by BioNTech and Pfizer, ...